Sanofi and GSK begin human trials for their COVID-19 vaccine; steroids prove effective in severe COVID-19 cases; a drug combination poses a breakthrough in ALS treatment.
Drug makers Sanofi and GlaxoSmithKline (GSK) announced they have started a clinical trial of their protein-based coronavirus disease 2019 (COVID-19) vaccine candidate, Reuters reports. The companies expect to reach the final testing stage by December 2020 and hope to produce up to one billion doses in 2021. The current stage aims to evaluate the safety, tolerability, and immune response in 440 healthy adults across 11 sites in the United States. The vaccine uses the same protein-based technology as one of Sanofi’s influenza vaccines and is combined with an adjuvant, or booster, developed by GSK.
Results from 3 studies show inexpensive and widely available steroids are the most effective treatment for serious COVID-19 cases found to date, NPR reports. Although steroids help suppress the immune system’s potentially deadly overreaction to an infection, some doctors were initially cautious to administer the drugs to patients with COVID-19, as steroids may also prevent the body from fighting off the virus. However, results from the studies found the use of systemic corticosteroids can reduce the risk of death by one-third in individuals hospitalized with COVID-19 compared with usual care or placebo.
Results from a 6-month study of 137 patients show the combination of 2 experimental drugs appears to slow decline in patients with amyotrophic lateral sclerosis (ALS), according to NPR. All patients enrolled in the trial had a fast-progressing form of the disease and those who received the 2-drug combination (AMX0035) scored several points higher on a standard measure of function. Although the difference was modest, results were meaningful to patients for whom continued use of their hands to cut food or type emails is a major benefit. The results are far from a cure for the disease, but lead investigator Sabrina Paganoni, MD, PhD, is convinced the findings mark the beginning of a new era in ALS treatment discovery.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More